Anticlastogenic and hepatoprotective effects of Kolaviron on sodium valproate-induced oxidative toxicity in Wistar rats

Figures & data

Figure 1. Structure of Kolaviron

Table 1. Experimental design

Treatment groups	Treatment (14 days)
A. Control	Distilled water
B. Kolaviron (KV)	200 mg/kg body weight
C. Sodium valproate (SVP)	500 mg/kg body weight
D. Kolaviron + Sodium valproate (KV + SVP)	500 mg/kg body weight + 200 mg/kg body weight

Figure 2. Protective effects of Kolaviron on sodium valproate-induced changes in the plasma activities of aspartate aminotransferase (a), alanine aminotransferase (b) and alkaline phosphatase (c) in rats. Data represent the means ± SD for six rats in each group; * significantly different from the Control; # significantly different from sodium valproate (P< 0.05)

Figure 3. Effect of Kolaviron on plasma concentration of advanced-oxidized protein products (a) and total thiol (b) in sodium valproate-induced toxicity in Wistar rats. Data represent the means ± SD for six rats in each group; * significantly different from the control; # significantly different from sodium valproate (P< 0.05)

Figure 4. Protective effect of Kolaviron co-treatment against sodium valproate-induced changes in hepatic biomarkers of oxidative stress in rats. Data represent the means ± SD for six rats in each group; * significantly different from the Control; # significantly different from sodium valproate (P< 0.05). (a): superoxide dismutase activity, (b): catalase activity, (c): glutathione S-transferase activity, (d): reduced glutathione

Figure 5. Protective effect of Kolaviron on VPA-induced toxicity on LPO (MDA) level in rats. Data represent the means ± SD for six rats in each group; * significantly different from the control; # significantly different from sodium valproate (P< 0.05)

Figure 6. Effects of co-treatment with Kolaviron on the generation of percentage DNA fragmentation in rats treated with sodium valproate. Data represent the means ± SD for six rats in each group; * significantly different from the control; # significantly different from sodium valproate (P< 0.05)

Figure 7. Effects of co-treatment with Kolaviron on frequency of occurrence of micronucleated polychromatic erythrocytes (mPCEs) in rats treated with sodium valproate. Data represent the means ± SD for six rats in each group; * significantly different from the control; # significantly different from sodium valproate (P < 0.05)